← Back to Search

Radiation Therapy

MR-guided Linac for Prostate Cancer

N/A
Waitlist Available
Led By Jonathan Leeman, MD
Research Sponsored by Dana-Farber Cancer Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights

Study Summary

This trial is testing a new radiation therapy that uses MRIs to better target cancer cells. The first phase will test if it is safe andPhase 2 will test if it is effective.

Eligible Conditions
  • Prostate Cancer
  • Nodal Metastases
  • Pancreatic Cancer
  • Mesothelioma
  • Liver Metastases
  • Lung Cancer
  • Kidney Cancer
  • Adrenal Metastases
  • Spinal Metastases
  • Brain Tumor

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Delivery Success Rate for SMART across multiple tumors-Phase I
Plan creation-Phase I
Rate of Improvement in Tumor Control-Phase II
+1 more
Secondary outcome measures
Disease Specific Survival Rate-Phase II
Duration of treatment-Phase 1
Number of Participants with long term toxicity-Phase II
+3 more

Trial Design

19Treatment groups
Experimental Treatment
Group I: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Synchronous Oligometastatic Nodes/Soft TissueExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group II: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--SpineExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group III: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Single-Fraction Kidney TumorsExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group IV: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--RenalExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group V: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Prostate BoostExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group VI: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--ProstateExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group VII: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Post-Operative Radiation Therapy in Lung CancerExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group VIII: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Pelvic Re-IrradiationExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group IX: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--PancreaticExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group X: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Oligoprogressive Oligometastatic Nodes/Soft TissueExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group XI: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Metachronous Oligometastatic NodesExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group XII: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--MesotheliomaExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group XIII: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Mediastinal and Hilar Lymph NodesExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group XIV: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Liver MetastasesExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group XV: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Central LungExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group XVI: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Brain MetastasesExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group XVII: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Borderline Resectable PancreasExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group XVIII: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Adrenal MetastasesExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards
Group XIX: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--1/3 Fraction for Oligometastatases in the Abdomen/PelvisExperimental Treatment1 Intervention
SMART will be administered per each individual disease site standards

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor
1,079 Previous Clinical Trials
340,551 Total Patients Enrolled
76 Trials studying Prostate Cancer
15,708 Patients Enrolled for Prostate Cancer
Jonathan Leeman, MDPrincipal Investigator - Brigham and Women's Hospital
Dana-Farber Cancer Institute
3 Previous Clinical Trials
371 Total Patients Enrolled
2 Trials studying Prostate Cancer
271 Patients Enrolled for Prostate Cancer

Media Library

Stereotactic Magnetic Resonance Guided Radiation Therapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT04115254 — N/A
Prostate Cancer Research Study Groups: PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Metachronous Oligometastatic Nodes, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--1/3 Fraction for Oligometastatases in the Abdomen/Pelvis, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Central Lung, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Single-Fraction Kidney Tumors, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Pancreatic, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Liver Metastases, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Prostate Boost, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Spine, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Post-Operative Radiation Therapy in Lung Cancer, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Borderline Resectable Pancreas, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Mediastinal and Hilar Lymph Nodes, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Brain Metastases, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Adrenal Metastases, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Pelvic Re-Irradiation, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Renal, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Oligoprogressive Oligometastatic Nodes/Soft Tissue, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Synchronous Oligometastatic Nodes/Soft Tissue, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Prostate, PHASE 1: SBRT MR IMAGE GUIDANCE/ADAPTATION--Mesothelioma
Prostate Cancer Clinical Trial 2023: Stereotactic Magnetic Resonance Guided Radiation Therapy Highlights & Side Effects. Trial Name: NCT04115254 — N/A
Stereotactic Magnetic Resonance Guided Radiation Therapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04115254 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the highest number of participants in this clinical trial?

"Affirmative. Clinicaltrials.gov's records display that this clinical study, which was established on October 22nd 2019, is still enrolling participants. The trial necessitates 1000 enrollees across 2 medical centres."

Answered by AI

What effects do the researchers of this study hope to produce?

"Over the span of one calendar year, this trial will evaluate tumor visualization as its primary outcome. Secondary metrics include Disease Specific Survival Rate (represented by Kaplan-Meier curves), Number of Patients with Acute Toxicity and Number of treatment fractions; all three being evaluated in Phase 1."

Answered by AI

Is enrollment still available for this clinical research program?

"Affirmative. Information posted on clinicaltrials.gov suggests that this trial has been actively seeking participants since October 22nd 2019 and is currently recruiting for 1000 patients at two different locations."

Answered by AI

Who else is applying?

What state do they live in?
Massachusetts
What site did they apply to?
Dana Farber Cancer Institute
What portion of applicants met pre-screening criteria?
Met criteria
How many prior treatments have patients received?
3+

What questions have other patients asked about this trial?

How long is the screening process?
PatientReceived 2+ prior treatments
Recent research and studies
clinicaltrials.govStudy
Stereotactic Magnetic Resonance Guided Radiation Therapy
Jonathan Leeman, MD 2019. "Stereotactic Magnetic Resonance Guided Radiation Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04115254.
~7 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top